ADME testing or ADME/Tox are gaining popularity owing to the advantages attached to it such as cost and time curbing tool in the process of drug development. Pharmacokinetics of drug is studied in ADME testing. Introduction of computer based assays are also expected to provide this market with lucrative growth opportunities over the forecast period. Late stage drug failure, due to differential results in animal models and human body, represents a substantial burden on the drug development system with respect to time and cost. Drug manufactures are hence incorporating ADME/Tox in early developmental phase. Increasing adoption of ADME toxicology testing is expected to be major growth driver in coming six years.
To request a sample copy or view summary of this report, click the link below:
ADME toxicity testing market is bifurcated into in-vivo and in-vitro technologies. In-vivo technologies market was observed to be most mature market in 2013. On the other hand, in-vitro technologies market is expected to have lucrative growth during the forecast period. This lucrative growth is attributed to the increasing ethical concerns over animal usage in clinical trials. Insilico technologies and hepatocyte testing of in-vivo testing are gaining momentum due early ADME toxicology prediction. Use of computer modeling is trending due to associated increase throughput screening.
To request a sample copy or view TOC of this report, click the link below:
Geographically, the market is studied with respect to North America, Europe, Asia Pacific, Latin America and MEA. North America is expected to be most mature market, owing to larger of drug manufacturing organizations base coupled increasing R&D investments related to drug discovery. Asia Pacific is expected to register lucrative growth due...